对2016年3月~12月入住我院重症监护室使用并监测万古霉素血清谷浓度且肌酐清除率大于120 m L·min-1的患者的一般资料、万古霉素血清浓度、疗效等临床信息进行统计分析。57例患者、96例次万古霉素血清谷浓度中,仅21.88%(21/96)达到...对2016年3月~12月入住我院重症监护室使用并监测万古霉素血清谷浓度且肌酐清除率大于120 m L·min-1的患者的一般资料、万古霉素血清浓度、疗效等临床信息进行统计分析。57例患者、96例次万古霉素血清谷浓度中,仅21.88%(21/96)达到目标浓度(15~20 mg·L-1),多重线性回归分析显示,肌酐清除率、给药剂量及血浆白蛋白为影响万古霉素血清谷浓度的主要因素(P<0.05),万古霉素达标者与未达标者病死率比较差异无统计学意义(P>0.05)。高肌酐清除率重症患者万古霉素血清谷浓度临床达标率低,需密切监测血药浓度,及时调整治疗方案。展开更多
A best evidence topic was devised in light of a structured protocol. What is the advantage of （minl＂mally invasive） approach in （frail patients） undergoing （aortic valve replacement）？ In cardiac outpatient cl...A best evidence topic was devised in light of a structured protocol. What is the advantage of （minl＂mally invasive） approach in （frail patients） undergoing （aortic valve replacement）？ In cardiac outpatient clinic you review an 85-year old male with severe aortic valve stenosis, low left ventricular ejection fraction and creatinine clearance of less than 50 mL/min. Other comorbidities include treated pulmonary hypertension, mild cognitive impairment, marked limitation of ordinary physical activity and depression. You resolve to determine whether to recommend mim＇mally invasive or conventional aortic valve replacement （AVR） or transcathe- ter aortic valve implantation （TAVI）, however you are not sure of the differences of the impact of frailty on preopera- tive risk for each approach; hence you investigate the best evidence on the topic.展开更多
文摘对2016年3月~12月入住我院重症监护室使用并监测万古霉素血清谷浓度且肌酐清除率大于120 m L·min-1的患者的一般资料、万古霉素血清浓度、疗效等临床信息进行统计分析。57例患者、96例次万古霉素血清谷浓度中,仅21.88%(21/96)达到目标浓度(15~20 mg·L-1),多重线性回归分析显示,肌酐清除率、给药剂量及血浆白蛋白为影响万古霉素血清谷浓度的主要因素(P<0.05),万古霉素达标者与未达标者病死率比较差异无统计学意义(P>0.05)。高肌酐清除率重症患者万古霉素血清谷浓度临床达标率低,需密切监测血药浓度,及时调整治疗方案。
文摘A best evidence topic was devised in light of a structured protocol. What is the advantage of （minl＂mally invasive） approach in （frail patients） undergoing （aortic valve replacement）？ In cardiac outpatient clinic you review an 85-year old male with severe aortic valve stenosis, low left ventricular ejection fraction and creatinine clearance of less than 50 mL/min. Other comorbidities include treated pulmonary hypertension, mild cognitive impairment, marked limitation of ordinary physical activity and depression. You resolve to determine whether to recommend mim＇mally invasive or conventional aortic valve replacement （AVR） or transcathe- ter aortic valve implantation （TAVI）, however you are not sure of the differences of the impact of frailty on preopera- tive risk for each approach; hence you investigate the best evidence on the topic.
